Tag: Sanofi
Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate
The company announces their timeline for continued progress toward an FDA approved standardized therapy.
Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy
More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
Auvi-Q Takes Center Stage at School Nurse Conference
One example of the changing market dynamics for epinephrine auto-injectors in light of recent developments.
Mylan's Chairman Was Paid $97.6 Million
Despite 2016 being a year when everything seemed to implode for the marketer of EpiPen.
Sanofi Files Suit Against Mylan for Anti-Competitive EpiPen Strategy
More legal troubles for the embattled marketer of EpiPen.
Auvi-Q Goes On Sale Today with a Bold Pricing and Distribution...
Innovation and participation by insurers will be key to the successful reintroduction of the device.
Kaleo Takes a Bold Step as Auvi-Q Returns
The company pledges $0 out-of-pocket expenses for many when the auto-injector is reintroduced February 14. FAQ included in article.
The Reliability of Auvi-Q: An Interview with Eric Edwards
We discuss the changes kaléo is making to the manufacture and quality assurance of Auvi-Q prior to its reintroduction in 2017.
Epinephrine Auto-injectors: Where is the Long Promised Generic?
We were supposed to have a generic alternative last year. What's holding it up and when can we expect it?
